“Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.
“In a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer, Arun said there is evidence that PARP inhibitors as well as immunotherapy in combination with various agents may be effective in women with TNBC and BRCA1-related breast cancers, but the science isn’t there yet.”
Go to full article.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.
“IBM on Tuesday said 14 US cancer treatment centers would join a partnership to get personalized care treatment plans from the company’s Watson supercomputer.
“The project extends the use of Watson for cancer treatment based on a patient’s own DNA and insights from a large database of medical literature and studies.
” ‘Determining the right drug combination for an advanced cancer patient is alarmingly difficult, requiring a complex analysis of different sources of Big Data that integrates rapidly emerging clinical trial information with personalized gene sequencing,’ said Norman Sharpless, of the University of North Carolina’s Lineberger Comprehensive Cancer Center.
” ‘We are partnering with IBM in an effort to solve this decision problem with the help of cognitive technology and to improve the decisions we make with our patients to maximize their chance for cure.’ ”